Oculis Reports Q1 2025 Financial Results and Provides Company Update
Oculis Reports Q1 2025 Financial Results and Provides Company Update GlobeNewswire May 08, 2025 The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor's (OCS-05) positive results from the ACUITY trial in Acute Optic […]